NCT03882762View on ClinicalTrials.gov

A Clinical Study to Evaluate the Effect of Renal Impairment on the Pharmacokinetics of Cebranopadol

PHASE1CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

June 20, 2013

Primary Completion Date

September 17, 2014

Study Completion Date

September 17, 2014

Conditions
Pharmacokinetic
Interventions
DRUG

Cebranopadol 200 μg tablet

200 μg cebranopadol film-coated tablet was taken with 240 mL of water under fed conditions.

Trial Locations (2)

32809

US0002 Contract research organization, Orlando

33014-3616

US0001 Contract research organization, Miami

Sponsors

Collaborators (1)

Forest Laboratories
All Listed Sponsors
collaborator

Forest Laboratories

INDUSTRY

lead

Tris Pharma, Inc.

INDUSTRY